AltMountain

Venrock Adviser, LLC

New York, NY · CRD 169288
Hedge fund manager

Venrock Adviser, LLC is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $4.5 billion in regulatory assets under management. Its private funds, of all types, hold $4.5 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +66.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +154.4% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$4.5 billionForm ADV Item 5.F
Gross assets of private funds
$4.5 billionAll private fund types, Form ADV
Hedge funds managed
17 private funds in total
Employees
11Form ADV Item 5.A
Registration
SEC-registered adviserCRD 169288
Latest Form ADV
04/28/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Est. 2026 YTD+66.3%Through Q2 2026 · S&P 500 +9.5%
Est. 2-year return+154.4%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$3.3 billion33 positions, 2026-06-30
$69$162$254Q3 2024Q1 2025Q3 2025Q1 202613F est. $254S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+34.1%+14.8%
Q1 2026+24.1%-4.6%
Q4 2025+50.7%+2.4%
Q3 2025+30.4%+7.8%
Q2 2025+12.2%+10.4%
Q1 2025-25.3%-4.5%
Q4 2024-22.0%+2.1%
Q3 2024+19.0%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Largest disclosed holdings

  • Apogee Therapeutics Inc$1.1 billion
  • Oruka Therapeutics Inc$394.8 million
  • Erasca Inc$327.8 million
  • Spyre Therapeutics Inc$265.0 million
  • Dianthus Therapeutics Inc$115.0 million
  • Ocular Therapeutix Inc$101.6 million
  • Galecto Inc$93.7 million
  • Savara Inc$90.8 million
  • Jade Biosciences Inc$71.6 million
  • Cogent Biosciences Inc$63.6 million

As of 2026-06-30, from 13F filing by Venrock Adviser, LLC.

Private funds reported on Form ADV (5)

Fund
Gross assets
Minimum
Owners
Adviser
Venrock Healthcare Capital Partners Eg, L.P.
Delaware, United StatesHedge fund
Gross assets$1.5B
MinimumNone set
Owners74
AdviserVR Adviser, LLC
Venrock Opportunities Fund, L.P.
Delaware, United StatesPrivate equity fund
Gross assets$658M
MinimumNone set
Owners87
AdviserVR Adviser, LLC
Venrock Healthcare Capital Partners III, L.P.
Delaware, United StatesPrivate equity fund
Gross assets$574M
MinimumNone set
Owners67
AdviserVR Adviser, LLC
Venrock Healthcare Capital Partners II, L.P.
Delaware, United StatesPrivate equity fund
Gross assets$51.1M
MinimumNone set
Owners41
AdviserVR Adviser, LLC
Venrock Healthcare Capital Partners, L.P.
Delaware, United StatesPrivate equity fund
Gross assets$1.4M
MinimumNone set
Owners42
AdviserVR Adviser, LLC

As reported in the adviser's Form ADV filed Mar 28, 2024. Funds also listed from Form D are shown above.

Fund vehicles: feeder funds and single-deal vehicles (3)

Fund
Gross assets
Minimum
Owners
Adviser
VHCP Co-Investment Holdings III, LLC
Delaware, United StatesPrivate equity fund
Gross assets$58.9M
MinimumNone set
Owners167
AdviserVR Adviser, LLC
VHCP Co-Investment Holdings II, LLC
Delaware, United StatesPrivate equity fund
Gross assets$20.4M
MinimumNone set
Owners235
AdviserVR Adviser, LLC
VHCP Co-Investment Holdings, LLC
Delaware, United StatesPrivate equity fund
Gross assets$333K
MinimumNone set
Owners126
AdviserVR Adviser, LLC

Feeder funds invest through a master fund; single-deal vehicles (SPVs, co-investments, series) hold one investment.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures